Brief: Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases In Complete Response Rates In Advanced Cutaneous Squamous Cell Carcinoma
27/07/2023 12:09
July 27 (Reuters) - Checkpoint Therapeutics Inc
CKPT.O :
* CHECKPOINT THERAPEUTICS ANNOUNCES COSIBELIMAB LONGER-TERM
RESULTS DEMONSTRATING SUBSTANTIAL INCREASES IN COMPLETE RESPONSE
RATES IN ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA
* CHECKPOINT THERAPEUTICS INC - COSIBELIMAB CONTINUES TO
DEMONSTRATE A FAVORABLE SAFETY PROFILE
* CHECKPOINT THERAPEUTICS INC - BIOLOGICS LICENSE
APPLICATION
CURRENTLY UNDER REVIEW BY U.S. FDA; PDUFA GOAL DATE OF JANUARY
3, 2024
Source text for Eikon: ID:nGNX5HTGrD
Further company coverage: CKPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Checkpoint Therapeutics
See all newsCheckpoint Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Checkpoint Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Street View -India's Sun Pharma buying Checkpoint boosts its specialty portfolio, analysts say